Although some of these somatic mutations, i.e., mutations in NPM1, FLT3, and DNMT3A, have been taken into consideration in predicting disease relapse in AML patients after allo-HSCT (14–17), a comprehensive prediction model that systemically integrates recurrent mutational profiling for disease relapse is needed in AML with allo-HSCT. This evidence concerns the gene DNMT3A and acute myeloid leukemia.